Intracellular signaling by protein tyrosine phosphorylation is generally understood to govern many aspects of cellular behavior. The biological consequences of this signaling pathway are important because the levels of protein tyrosine phosphorylation are frequently elevated in cancer cells. In the classic paradigm, tyrosine kinases promote tumor cell growth, survival, and invasiveness, whereas tyrosine phosphatases negatively regulate these same behaviors. Here, we identify one particular tyrosine phosphatase, low molecular weight tyrosine phosphatase (LMW-PTP), which is frequently overexpressed in transformed cells. We also show that overexpression of LMW-PTP is sufficient to confer transformation upon non-transformed epithelial cells. Notably, we show that the EphA2 receptor tyrosine kinase is a prominent substrate for LMW-PTP and that the oncogenic activities of LMW-PTP result from altered EphA2 expression and function. These results suggest a role for LMW-PTP in transformation progression and link its oncogenic potential to EphA2.
Intracellular signaling by protein tyrosine phosphorylation is generally understood to govern many aspects of cellular behavior. The biological consequences of this signaling pathway are important because the levels of protein tyrosine phosphorylation are frequently elevated in cancer cells. In the classic paradigm, tyrosine kinases promote tumor cell growth, survival, and invasiveness, whereas tyrosine phosphatases negatively regulate these same behaviors. Here, we identify one particular tyrosine phosphatase, low molecular weight tyrosine phosphatase (LMW-PTP), which is frequently overexpressed in transformed cells. We also show that overexpression of LMW-PTP is sufficient to confer transformation upon non-transformed epithelial cells. Notably, we show that the EphA2 receptor tyrosine kinase is a prominent substrate for LMW-PTP and that the oncogenic activities of LMW-PTP result from altered EphA2 expression and function. These results suggest a role for LMW-PTP in transformation progression and link its oncogenic potential to EphA2.
Cancer arises when a population of cells gains the ability to inappropriately grow and survive. These biological behaviors often result from genetic and environmental abnormalities that work together to trigger specific signaling pathways that promote inappropriate cell growth and survival. In particular, increased levels of protein tyrosine phosphorylation are understood to initiate powerful signals that govern many different aspects of cell behavior (1) . A popular paradigm suggests that a balance between tyrosine kinase and phosphatase activities determines the cellular levels of protein tyrosine phosphorylation and thereby governs cellular decisions regarding growth, survival, and invasiveness (2) . This model predicts that tyrosine kinases are oncogenic, whereas tyrosine phosphatases negatively regulate transformation. Although this paradigm has generally been supported by the identification of oncogenic tyrosine kinases, emerging evidence reveals a more complex interplay between tyrosine kinases and phosphatases. For example, the PTP(CAAX) tyrosine phosphatase has been recently implicated as an oncogene (3) . Moreover, the enzymatic activity of Src family kinases is liberated by phosphatase-mediated dephosphorylation of critical tyrosine residues (4, 5) . In the latter situation, phosphatases can actually up-regulate protein tyrosine phosphorylation by increasing the enzymatic activity of kinases.
The EphA2 receptor tyrosine kinase is overexpressed in a large number of human cancers. High levels of EphA2 apply to a large number of different cancers, including breast, prostate, colon, and lung carcinomas as well as metastatic melanomas (6 -10) . The highest levels of EphA2 are consistently found on the most aggressive cell models of human cancer (9 -11). Moreover, EphA2 is not simply a marker of transformed disease as ectopic overexpression of EphA2 confers tumorigenic and metastatic potential upon non-transformed epithelial cells (10) .
In addition to its overexpression, EphA2 is functionally altered in transformed cells as compared with non-transformed epithelia (12) . In particular, EphA2 is prominently tyrosine phosphorylated in non-transformed epithelial cells. Yet, despite its overexpression, the EphA2 in transformed cells is not tyrosine phosphorylated (10 -12) . Recent studies indicate that these differences in EphA2 phosphotyrosine content are important because tyrosine phosphorylation of EphA2 causes it to interact with downstream signaling components that function to negatively regulate cell growth and invasiveness (10, (12) (13) (14) (15) (16) . In contrast, unphosphorylated EphA2 appears to adopt a different subcellular localization and interacts with different substrates (10 -12) . Most importantly, recent studies have shown that unphosphorylated EphA2 functions as a powerful oncoprotein, whereas restoration of EphA2 phosphotyrosine content is sufficient to reverse the oncogenic potential of EphA2 (10, 12, 13) .
Based on the differential behaviors of EphA2 in normal and transformed cells, our laboratory has been investigating the regulation of EphA2 phosphotyrosine content. Our recent studies have centered upon evidence that cancer cells often demonstrate decreased cell-cell contacts (17) (18) (19) , which destabilize ligand binding (10, 12) . Our present studies investigate an additional possibility, which is that the phosphotyrosine content of EphA2 in transformed cells is negatively regulated by an associated phosphatase. We affirm this hypothesis and identify LMW-PTP 1 as a phosphatase that regulates EphA2. Human LMW-PTP has been cloned, sequenced, expressed, and structurally characterized (20 -22) . We also demonstrate that LMW-PTP is overexpressed in many transformed cell lines and that overexpression of LMW-PTP is sufficient to confer transformation upon non-transformed epithelial cells. Moreover, we demonstrate that the oncogenic activities of LMW-PTP require EphA2.
MATERIALS AND METHODS
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ʈ To whom correspondence should be addressed: MedImmune, Inc., 35 West Watkins Mill Rd., Gaithersburg, MD 20878. Tel.: 240-632-4639; Fax: 301-527-4200; E-mail: kinchm@medimmune.com. cells were cultured as described previously (23) (24) (25) . Monoclonal antibodies specific for phosphotyrosine (PY20) and ␤-catenin were purchased from Transduction Laboratories (Lexington, KY). Monoclonal antibodies specific for phosphotyrosine (4G10) and EphA2 (clone D7) were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Monoclonal antibodies against vinculin were purchased from NeoMarkers (Fremont, CA). Purified LMW-PTP was prepared as described (20) .
Cell Lysates-Cell lysates were harvested and normalized for equal loading as described previously (18) . To confirm equal loading, blots were stripped as described previously and reprobed with antibodies specific to ␤-catenin or vinculin (18) .
Immunoprecipitation and Immunoblot Analyses-Immunoprecipitation of EphA2 or LMW-PTP were performed using rabbit anti-mouse (Chemicon, Temecula, CA)-conjugated protein A-Sepharose (Sigma) as described previously (12) . To confirm equal loading, blots were stripped as described previously and reprobed with EphA2-or LMW-PTP-specific antibodies (18) . Immunoblot analyses were performed on normalized cell lysates and immunoprecipitations as detailed (12) . Antibody binding was detected by enhanced chemiluminescence (ECL; Pierce) and visualized by autoradiography (Kodak X-OMAT; Eastman Kodak Co.).
EGTA and Pervanadate Treatments-"Calcium switch" experiments were performed as described previously using MCF-10Aneo cells grown to 70% confluence in medium containing a final concentration of 4 mM EGTA (12) . Pervanadate was added to MDA-MB-231 in monolayer culture at a final concentration of 0, 1, 10, or 100 M, and the treatment was allowed to incubate for 10 min at 37°C, 5% CO 2 . For the combined EGTA-pervanadate treatment, MDA-MB-231 cells were first treated with 100 M pervanadate and were then subjected to the EGTA treatment.
In Vitro Kinase and Phosphatase Assays-To evaluate LMW-PTP activity against EphA2, EphA2 was immunoprecipitated from MCF10Aneo cells and incubated with purified LMW-PTP protein at a concentration of 0.45, 7.8, or 62 g/ml for 0, 5, 15, or 30 min. The assay was terminated through the addition of Laemmli sample buffer. The phosphotyrosine content of the EphA2 in the treatments was then observed using immunoblot analysis with antibodies specific to phosphotyrosine. To determine in vitro autophosphorylation activity, immunoprecipitated EphA2 was evaluated using in vitro kinase assays as detailed previously (12) .
Transfection and Selection-Monolayers of MCF-10Aneo cells were grown to 30 -50% confluence and were transfected with pcDNA3.1-LMW-PTP or pcDNA3.1-LMW-PTP D129A using LipofectAMINE PLUS (Invitrogen). As a control for the transfection procedure, empty pcDNA3.1 vector was transfected into the same cell line in parallel. Transient transfections were allowed to grow for 48 h after transfection. For stable lines, neomycin-resistant cells were selected in growth medium containing 16 g/ml neomycin (Mediatech, Inc., Herndon, VA). To confirm LMW-PTP overexpression, immunoblot analysis was performed using LMW-PTP-specific antibodies. Parental cells and cells transfected with empty pcDNA3.1 vector were used as negative controls.
Growth Assay-To evaluate cell growth using monolayer assays, 1 ϫ 10 5 cells were seeded into tissue culture-treated multiwell dishes for 1, 2, 4, or 6 days in triplicate experiments. Cell numbers were evaluated by trypsin suspension of the samples followed by microscopic evaluation using a hemacytometer. Soft agar colony formation was performed and quantified as detailed (10, 26) . For experiments with EphA2 antisense, cells were incubated with oligonucleotides prior to suspension in soft agar. The data shown are representative of at least three different experiments.
Antisense Treatment-Monolayers of MCF-10Aneo cells and MCF-10A cells stably overexpressing LMW-PTP were grown to 30% confluence and were transfected with EphA2 antisense oligonucleotides as detailed (13) . Samples that had been transfected with an inverted EphA2 antisense oligonucleotide or with the transfection reagent alone provided negative controls.
RESULTS

EphA2
Is Regulated by an Associated Tyrosine Phosphatase-Several independent lines of investigation suggested that EphA2 is regulated by an associated tyrosine phosphatase. EphA2 was rapidly dephosphorylated in non-transformed MCF-10Aneo epithelial cells upon disruption of ligand binding. Immunoblot analysis with phosphotyrosine antibodies (PY20 or 4G10) indicated lower levels of EphA2 phosphotyrosine content within 5 min following EGTA treatment, which destabilizes EphA2-ligand binding (12) (Fig. 1A) . Similarly, tyrosine phosphorylation of EphA2 decreased following incubation of non-transformed epithelial cells with dominant-negative inhibitors of EphA2-ligand binding (e.g. EphA2-F c , not shown). Similar results were obtained using multiple non-transformed epithelial cell systems, including MCF-12A, MCF10-2, HEK293, Madin-Darby canine kidney, and Madin-Darby bovine kidney cells (not shown). Based on these findings, we asked whether tyrosine phosphatase inhibitors could prevent the loss of EphA2 phosphotyrosine content in response to EGTA treatment. Indeed, inhibitors such as sodium orthovanadate prevented the decrease in EphA2 phosphotyrosine following treatment of MCF-10Aneo cells with EGTA (Fig. 1B) .
Previous studies by our laboratory have shown that the phosphotyrosine content of EphA2 is greatly reduced in transformed epithelial cells as compared with non-transformed epithelia (10, 12) . Thus, we asked whether tyrosine phosphatase activity could contribute to the reduced phosphotyrosine content of EphA2 in transformed cells. Although EphA2 was not tyrosine phosphorylated in transformed breast cancer cells (MDA-MB-231, MDA-435, MCFneoST, or PC-3 cells), incubation with increasing concentrations of sodium orthovanadate induced vigorous tyrosine phosphorylation of EphA2 (Fig. 1C) . As vanadate treatment of cells can often lead to exaggerated phosphorylation of physiologically irrelevant sites, we performed phosphopeptide mapping studies using EphA2 that had been labeled with [ 32 P]ATP either in vitro or in vivo (not shown). These studies revealed identical patterns of tyrosine phosphorylation in non-transformed MCF-10Aneo cells and vanadate-treated MDA-MB-231 cells (not shown). Although the cytoplasmic domain contains multiple sites that could have been phosphorylated promiscuously, these were not phosphorylated under the conditions utilized here, suggesting that vanadate had not increased the phosphorylation of irrelevant sites. Altogether, these results indicate that EphA2 is regulated by an associated phosphatase that suppresses EphA2 phosphotyrosine content in transformed cells.
LMW-PTP Interacts with and Dephosphorylates EphA2-To identify tyrosine phosphatases that might regulate EphA2 in FIG. 1. EphA2 is regulated by an associated phosphatase. In A, monolayers of MCF-10Aneo human mammary epithelial cells were incubated in the presence or absence (denoted as C for control) of 4 mM EGTA for 20 min before detergent extraction. The samples were resolved by SDS-PAGE and probed with phosphotyrosine (P-Tyr)-specific antibodies (PY20 and 4G10; top). The membranes were stripped and reprobed with EphA2-specific antibodies to confirm equal sample loading (below). In B, MCF-10Aneo cells were treated with EGTA, as detailed above, in the presence or absence of NaVO 4 to inhibit phosphatase activity. In C, EphA2 was immunoprecipitated from MDA-MB-231 cells that had been incubated in the presence of the indicated concentrations of NaVO 4 for 10 min at 37°C.
transformed cells, we considered a recent report that LMW-PTP regulates a related molecule, EphB4 (27) . Our initial experiments began by assessing the expression and function of LMW-PTP in non-transformed (MCF-10Aneo) and transformed (MCF-7, SK-BR-3, MDA-MB-435, MDA-MB-231) mammary epithelial cells (Fig. 2) . Immunoblot analyses of whole cell lysates revealed relatively high levels of LMW-PTP in tumor-derived breast cancer cells as compared with non-transformed MCF10Aneo mammary epithelial cells. The membranes were stripped and reprobed with antibodies against a control protein (vinculin), verifying that the high levels of LMW-PTP did not reflect a loading error or a generalized increase in protein levels in the transformed cells. A transformed variant of MCF10Aneo, MCFneoST, also demonstrated elevated LMW-PTP expression, which was intriguing based on a recent report that EphA2 is not tyrosine phosphorylated in those cells (11) . The use of a genetically matched system also precluded potential differences due to cell origin or culture conditions. Thus, the highest levels of LMW-PTP were consistently found in transformed epithelial cells and were inversely related to EphA2 phosphotyrosine content.
The results suggested that LMW-PTP negatively regulates the phosphotyrosine content of EphA2 in tumor cells. To explore this hypothesis further, we first asked whether the two molecules interacted in vivo. EphA2 was immunoprecipitated from MDA-MB-231 cells using specific antibodies (clone D7), and these complexes were resolved by SDS-PAGE. Subsequent immunoblot analyses revealed that LMW-PTP was prominently found within EphA2 immune complexes (Fig. 3A) . The inverse experiment confirmed that EphA2 could similarly be detected in complexes of immunoprecipitated LMW-PTP (Fig.  3B ). Control immunoprecipitations with irrelevant antibodies confirmed the specificity of the interactions of the two molecules (not shown).
The co-immunoprecipitation studies did not clarify whether EphA2 can serve as a substrate for LMW-PTP. To address this directly, EphA2 was immunoprecipitated from MCF-10Aneo cells, where it is normally tyrosine phosphorylated. The EphA2 immune complexes were then incubated with different concentrations of purified LMW-PTP before immunoblot analyses of EphA2 with phosphotyrosine-specific antibodies (PY20 and 4G10). These experiments demonstrated that purified LMW-PTP could dephosphorylate EphA2 in a dose-and time-dependent manner (Fig. 4) .
Although in vitro studies indicated that EphA2 could be dephosphorylated by LMW-PTP in vitro, we recognized that in vitro studies are not always representative of the corresponding situation in vivo. Thus, LMW-PTP was ectopically overexpressed in MCF-10A cells. This particular cell system was selected because non-transformed MCF-10A cells have low levels of endogenous LMW-PTP and because the EphA2 in these non-transformed epithelial cells is normally tyrosine phosphorylated. Ectopic overexpression of LMW-PTP was achieved by stable transfection, as determined by immunoblot analyses with specific antibodies (Fig. 5A) . Importantly, overexpression of LMW-PTP was sufficient to reduce the phosphotyrosine content of EphA2 as compared with vector-transfected negative controls (Fig. 5B) . Identical results were obtained using different experiments with different transfectants and in both stably and transiently transfected samples (not shown), thus eliminating potential concerns about clonal variation. Moreover, the decreased phosphotyrosine content was specific for EphA2 as the overall phosphotyrosine content of LMW-PTP-overexpressing cells was not decreased (Fig. 5C) .
LMW-PTP Overexpression Causes Transformation of Epithelial Cells-Tyrosine phosphorylated EphA2 negatively regulates tumor cell growth, whereas unphosphorylated EphA2 acts as a powerful oncoprotein (10, 12, 13) . Thus, we asked whether overexpression of LMW-PTP would be sufficient to induce transformation. To address this question, we utilized the MCF-10A cells, described above, which had been transfected with either wild-type LMW-PTP or a vector control. Our initial studies evaluated the growth rates of control and LMW-PTP-overexpressing cells in monolayer culture. When evaluated using standard, two-dimensional culture conditions, the 
FIG. 4. EphA2 can serve as a substrate for LMW-PTP in vitro.
EphA2 was immunoprecipitated from 5 ϫ 10 6 MCF-10Aneo cells before incubation with the indicated amounts of LMW-PTP protein for 0 -30 min at 37°C. The samples were then resolved by SDS-PAGE and subjected to immunoblot analysis with phosphotyrosine (P-Tyr)-specific antibodies. The membranes were stripped and reprobed with EphA2-specific antibodies to confirm equal sample loading. IP, immunoprecipitates.
growth rates of LMW-PTP-overexpressing MCF-10A cells were significantly lower than the growth rates of matched controls (p Ͻ 0.05) (Fig. 6A) .
Two-dimensional assessments of growth often do not reflect the transformed character of tumor cells. Instead, three-dimensional analyses of cell behavior using soft agar and reconstituted basement membranes can provide a more relevant way of assessing transformed behavior. Whereas vector-transfected MCF-10Aneo cells were largely incapable of colonizing soft agar, LMW-PTP-overexpressing cells formed an average of 4.9 colonies per high powered microscope field (p Ͻ 0.01; Fig. 6B ). Based on recent findings with other three-dimensional assay systems, we also evaluated cell behavior using three-dimensional, reconstituted basement membranes. Consistent with a more aggressive phenotype, microscopic assessment of cell behavior in Matrigel confirmed the transformed character of LMW-PTP-overexpressing cells (not shown). When plated atop or within Matrigel, LMW-PTP-overexpressing cells formed larger colonies than vector-transfected cells (not shown). Altogether, consistent results with multiple and different systems suggest that overexpression of LMW-PTP is sufficient to induce transformation.
The Transformed Phenotype of LMW-PTP-Overexpressing Cells Requires EphA2-Tyrosine phosphorylation of EphA2 induces its internalization and degradation (13) . Thus, we postulated that overexpression of LMW-PTP might increase the protein levels of EphA2. Indeed, immunoblot analyses of whole cell lysates revealed higher levels of EphA2 in MCF-10A cells that overexpress LMW-PTP as compared with vector-transfected controls (Fig. 5A) . Moreover, this EphA2 was not tyrosine phosphorylated (Fig. 5B) . However, immunoblot analyses revealed that the reduced phosphotyrosine content was selective for EphA2 as the general levels of phosphotyrosine were not altered in LMW-PTP-transformed cells (Fig. 5C) .
The finding that overexpression of LMW-PTP increased EphA2 protein levels and decreased its phosphotyrosine content was intriguing since this phenotype was reminiscent of highly aggressive tumor cells (10, 12) . Thus, we asked whether selective targeting of LMW-PTP in transformed cells would impact EphA2. To accomplish this, the catalytically inactive (28) mutant LMW-PTP D129A was overexpressed in MDA-MB-231 cells, which have high levels of wild-type LMW-PTP (Fig. 2) and which also have elevated levels of EphA2 that is hypophosphorylated. Ectopic overexpression of LMW-PTP D129A was found to decrease the levels of EphA2. Moreover, immunoblot analyses of immunoprecipitated material demonstrated that EphA2 was tyrosine phosphorylated (Fig. 5D) . These results indicate that overexpression of wild-type LMW-PTP is necessary and sufficient to confer the overexpression and functional alterations of EphA2 that have been observed in tumor-derived cells.
Although the EphA2 in the LMW-PTP-overexpressing MCF-10A cells was not tyrosine phosphorylated, it retained enzymatic activity. In vitro kinase assays verified that the EphA2 from LMW-PTP-transformed MCF-10A cells had levels of enzymatic activity that were comparable with vector-transfected controls (Fig. 7A) . To verify equal sample loading, two controls were performed. Equal amounts of input lysate were verified by immunoblot analyses with ␤-catenin antibodies (not shown). In addition, the immunoprecipitated EphA2 was divided, and half
FIG. 5. LMW-PTP dephosphorylates EphA2 in vivo.
A-C, MCF-10A cells stably transfected with expression vectors that encode for wild-type LMW-PTP. In A, detergent lysates were resolved by SDS-PAGE and subjected to immunoblot analyses with LMW-PTP antibodies, with purified LMW-PTP providing a positive control (top). Parallel samples were probed for EphA2 protein levels (middle). The membranes were stripped and reprobed with ␤-catenin antibodies as a loading control (bottom). In B, equal amounts of EphA2 were isolated by immunoprecipitation, resolved by SDS-PAGE, and subjected to immunoblot analyses with EphA2 (top)-or P-Tyr-specific (bottom) antibodies. Note that this experiment compared the phosphotyrosine content using equal amounts of EphA2 (to obviate potential concerns about sample loading) as compared with panel A, which evaluated EphA2 levels in equal amounts of cell lysate. IP, immunoprecipitates. In C, cell lysates were harvested from control or LMW-PTP-transfected cells, and equal amounts of protein were resolved by SDS-PAGE and evaluated by immunoblot analyses using phosphotyrosine-specific antibodies. In D, the protein levels (top) and phosphotyrosine content (bottom) of immunoprecipitated EphA2 were evaluated using material isolated from MDA-MB-231 cells that had been transfected with a dominant-negative phosphatase mutant (LMW-PTP D129A ) or a matched vector control.
FIG. 6. LMW-PTP enhances transformed character.
In A, to evaluate anchorage-dependent cell growth, 1 ϫ 10 5 control or LMW-PTP-transfected MCF-10A cells were seeded into monolayer culture, and cell numbers were evaluated microscopically at the intervals shown. In B, in parallel studies, the control and LMW-PTP-transfected cells were suspended in soft agar. Colony formation (per high powered field (HPF)) after 5 days of incubation at 37°C is shown. These results were representative of at least three separate experiments. *, p Ͻ 0.01. of the material was resolved by SDS-PAGE and analyzed by immunoblot analyses with EphA2 and phosphotyrosine-specific antibodies (Fig. 7, B and C) . Thus phosphorylated and unphosphorylated EphA2 were both capable of enzymatic activity.
Having determined that the levels of EphA2 were elevated in LMW-PTP-transformed cells, we asked to what extent the oncogenic activity of EphA2 contributed to this phenotype. To address this, we utilized our experience with antisense strategies to selectively decrease EphA2 expression in LMW-PTPtransformed cells (13, 29) . We verified the success of these strategies by immunoblot analyses (Fig. 8A ) and then asked whether decreased EphA2 expression would alter soft agar colonization. Indeed, transfection with EphA2 antisense oligonucleotides decreased the soft agar colonization of LMW-PTPtransformed MCF-10A cells by at least 87% (p Ͻ 0.01; Fig. 8B ). As a control, transfection of these cells with an inverted antisense nucleotide did not significantly alter soft agar colonization. Thus, we were able to exclude that the results with the antisense oligonucleotides had resulted from nonspecific toxicities caused by the transfection procedure. Altogether, our results indicate that the oncogenic actions of overexpressed LMW-PTP require high levels of EphA2.
DISCUSSION
The major finding of our present study is that EphA2 is regulated by an associated tyrosine phosphatase, and we identify LMW-PTP as a critical regulator of EphA2 tyrosine phosphorylation. We also demonstrate that LMW-PTP is overexpressed in metastatic cancer cells and that LMW-PTP overexpression is sufficient to confer transformation upon nontransformed epithelial cells. Finally, we demonstrate that LMW-PTP up-regulates the expression of EphA2 and that the oncogenic activities of LMW-PTP require this overexpression of EphA2.
Recent reports from our laboratory and others have shown that many transformed epithelial cells express high levels of EphA2 that is not tyrosine phosphorylated (10, 12) . Previously, we had related these depressed levels of EphA2 tyrosine phosphorylation with decreased ligand binding. Transformed cells often have unstable cell-cell contacts, and we postulated that this decreases the ability of EphA2 to stably interact with its ligands, which are anchored to the membrane of adjacent cells (12) . In part, our present data suggest a new paradigm in which the phosphotyrosine content of EphA2 is also negatively regulated by an associated tyrosine phosphatase that is overexpressed in transformed cells. Given the relationship between EphA2 phosphorylation and cell-cell adhesion, we cannot exclude that cell-cell contacts could also regulate the expression or function of LMW-PTP, and future investigation should address this possibility.
The fact that high levels of LMW-PTP were observed in several different cell models of metastatic cancer is notable given that LMW-PTP overexpression is sufficient to confer transformation. LMW-PTP-overexpressing cells gain the ability to colonize soft agar and acquire a transformed phenotype when cultured in three-dimensional basement membranes, such as Matrigel. Notably, however, LMW-PTP-overexpressing MCF-10A epithelial cells displayed reduced rates of cell growth as measured using two-dimensional assays of cell growth. This latter observation is consistent with recent reports that high levels of LMW-PTP similarly decrease the monolayer growth rates of other cell types (30, 31) . Although such a finding had been interpreted to suggest that LMW-PTP might negatively regulate transformation, our findings support a very different conclusion. Consistent with this, recent studies by our laboratory and others have shown that transformation of MCF-10A cells is often accompanied by decreased monolayer growth rates and that the most aggressive variants of MCF-10A in vivo demonstrate the slowest growth in monolayer culture (10, 11, 32) . These findings have implications for the design and interpretation of tests of oncogene function when using non-transformed epithelial cell systems.
The biochemical consequences of EphA2 tyrosine phosphorylation remain largely unclear. Unlike other receptor tyrosine kinases, for which autophosphorylation is necessary for enzymatic activity, tyrosine phosphorylation of EphA2 is not required for its enzymatic activity. Consistent with our present results, EphA2 retains comparable levels of enzymatic activity in non-transformed and tumor-derived cells, despite dramatic differences in its phosphotyrosine content (12) . Similarly, an-FIG. 7. EphA2 retains enzymatic activity in LMW-PTP-transformed cells. Equal amounts of EphA2 were immunoprecipitated from control or LMW-PTP-transformed MCF-10A cells and subjected to in vitro kinase assays. In A, autophosphorylation with ␥-32 P-labeled ATP was evaluated by autoradiography. To confirm equal sample loading, a portion of the immunoprecipitated materials was evaluated by immunoblot analyses with EphA2 (B) or phosphotyrosine (P-Tyr) (C) antibodies. Whereas EphA2 is not tyrosine phosphorylated in LMW-PTP-transformed cells, it retains enzymatic activity. Note that equal amounts of EphA2 were utilized for these results to overcome differences in endogenous EphA2 expression (as discussed in the legend for In A, immunoblot analysis using EphA2-specific antibodies confirmed that the antisense treatment decreased EphA2 protein levels (top). The membrane was then stripped and reprobed for ␤-catenin to confirm equal sample loading (bottom). In B, parallel samples were suspended and incubated in soft agar for 5 days. The average number colonies per high powered microscopic field (HPF) are shown. *, p Ͻ 0.01.
tibody-mediated stimulation of EphA2 autophosphorylation does not change the levels of EphA2 enzymatic activity (13) . Phosphopeptide analyses of the EphA2 cytoplasmic domain provide one potential explanation. Although EphA2 has a predicted activation loop tyrosine at residue 772 (33) , neither in vitro nor in vivo phosphopeptide analyses have identified phosphorylation of this site in normal or malignant cells. 2 Thus, the lack of a consensus activation loop tyrosine may account for the retention of EphA2 enzymatic activity in cells where it is not tyrosine phosphorylated.
Tyrosine phosphorylation of EphA2 does not appear to be necessary for its intrinsic enzymatic activity. Instead, ligandmediated tyrosine phosphorylation regulates EphA2 protein stability (13) . Specifically, tyrosine phosphorylation fates EphA2 to interact with the c-Cbl adapter protein and to subsequently be internalized and degraded within proteosomes. 3 Consequently, the phosphatase activity of LMW-PTP would be predicted to increase EphA2 protein stability. Indeed, the highest levels of EphA2 are consistently found in cells with high levels of LMW-PTP. One interesting implication of this finding is that it provides a mechanism, independent of genetic regulation of the EphA2 gene, to explain why high levels of EphA2 are found in many different tumors. An alternative possibility is that LMW-PTP up-regulates EphA2 gene expression, and our present findings do not formally eliminate this possibility. The fact that EphA2 antisense oligonucleotides reversed the transformed character of LMW-PTP-overexpressing cells suggests that the up-regulation of EphA2 is relevant to the cellular behaviors of LMW-PTP-mediated transformation.
In summary, our present studies identify LMW-PTP as a new oncogene that is overexpressed in transformed cells. We also link the biochemical and biological actions of overexpressed LMW-PTP with EphA2. These findings have important implications for understanding the biochemical and biological mechanisms that contribute to the metastatic progression of epithelial cells. Moreover, our present studies identify an important signaling system that could ultimately provide an opportunity to target the large number of cancer cells that overexpress EphA2 or LMW-PTP.
